Evidence map›Paper›PMID 40877519›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Developing Aptamer-Targeted mRNA for Immunotherapy.

Alexandra R Paul, Khuloud T Al-Jamal

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexandra R PaulDepartment of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR.
Khuloud T Al-JamalDepartment of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR. kaljamal@hku.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective protein expression plays a crucial role in mRNA therapeutics. In this chapter, we present a novel T-cell-targeting aptamer drug delivery platform that enables efficient mRNA delivery to immune cells for immunotherapy. We outline protocols for aptamer selection, aptamer-mRNA conjugation, characterization, and transfection into T-cells. Our results show that the OX40 mRNA-conjugated T-cell aptamer enhances mRNA transfection in murine ex vivo splenocyte T-cells, achieving a fourfold increase in CD4+ cells and a sevenfold increase in CD8+ cells compared to untargeted OX40 mRNA. This platform can be customized for other targets via aptamer selection, facilitating the development of enhanced mRNA therapies.

Indexed as

Aptamers, NucleotideImmunotherapyRNA, MessengerAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansMiceReceptors, OX40TransfectionAptamers, NucleotideReceptors, OX40RNA, MessengerAptamersFlow cytometryGel electrophoresisImmunotherapymRNA deliveryNucleic acidsTransfection

Identifiers

PMID40877519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.